Hypereosinophilic Syndrome (HES) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Hypereosinophilic Syndrome (HES) is a group of disorders characterized by elevated blood eosinophil counts (>1.5 × 109/L) and resultant organ damage, commonly affecting the heart. Initially, the term referred to the combination of peripheral blood eosinophilia and tissue infiltrates leading to dysfunction or damage. The "idiopathic" label reflected the lack of knowledge regarding underlying causes, excluding known diseases such as drug allergies, parasitic infections, cancer, lymphoma and myeloproliferative disorders. Symptoms of HES can vary greatly among patients and include skin rashes, dizziness, memory loss, coughing, shortness of breath, fatigue, fever, and mouth sores. Organ damage or dysfunction occurs due to the release of cytotoxic substances by eosinophils, including eosinophil cationic protein, major basic protein, ribonuclease eosinophil derived neurotoxin, eosinophil peroxidase, and enzymes such as elastase and collagenase. Eosinophils also secrete cytokines and chemokines, contributing to the immune response, and can lead to fibrotic changes due to increased collagen synthesis. Current diagnostic criteria for HES suggest that two distinct mechanisms may underlie chronic, unexplained hypereosinophilia in HES patients. One mechanism involves a sporadic hematopoietic stem cell mutation resulting in clonal expansion of eosinophilic cells, and the other involves an overproduction of eosinophilopoietic cytokines by activated T cells. Classifying HES patients can be challenging and requires specialized laboratory evaluation. Predominant skin symptoms without heart involvement, along with serum hyper IgE or polyclonal hypergammaglobulinemia, may suggest the lymphocytic variant of HES. Treatment options for HES include high-dose oral corticosteroids, interferon alpha, hydroxyurea, and PUVA therapy. Approximately 70% of patients respond to oral prednisone therapy with normalization of eosinophil counts. The 5-year survival rate for HES patients is 80%, with heart failure being the most common cause of death.

·       The incidence of HES ranged from 0.04 to 0.17 per 100,000 individuals.

Thelansis’s “Hypereosinophilic Syndrome (HES) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypereosinophilic Syndrome (HES) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Hypereosinophilic Syndrome (HES) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hypereosinophilic Syndrome (HES) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Hypereosinophilic Syndrome (HES) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more